In the last four years, six new drugs have been approved by the United States Food and Drug Administration for the treatment of kidney cancer. They are:
sorafenib, bevacizumab, sunitinib, temsirolimus, everolimus, and pazopanib
In the last four years, six new drugs have been approved by the United States Food and Drug Administration for the treatment of kidney cancer. They are:
sorafenib, bevacizumab, sunitinib, temsirolimus, everolimus, and pazopanib